These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 32179982)

  • 21. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
    Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
    Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
    Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
    Tubridy EA; Eiva MA; Liu F; Omran DK; Gysler S; Brown EG; Roy AG; Zeng Y; Oh J; Cao Q; Gitto SB; Powell DJ
    Gynecol Oncol; 2024 May; 184():74-82. PubMed ID: 38290413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
    Scurry J; van Zyl B; Gulliver D; Otton G; Jaaback K; Lombard J; Vilain RE; Bowden NA
    Gynecol Oncol; 2018 Nov; 151(2):306-310. PubMed ID: 30194007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
    Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
    J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy.
    Yaniz-Galende E; Zeng Q; Bejar-Grau JF; Klein C; Blanc-Durand F; Le Formal A; Pujade-Lauraine E; Chardin L; Edmond E; Marty V; Ray-Coquard I; Joly F; Ferron G; Pautier P; Berton-Rigaud D; Lortholary A; Dohollou N; Desauw C; Fabbro M; Malaurie E; Bonichon-Lamaichhane N; Bello Roufai D; Gantzer J; Rouleau E; Genestie C; Leary A
    Clin Cancer Res; 2024 Jul; 30(13):2790-2800. PubMed ID: 38669064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
    Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
    Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH
    Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Matsuo K; Matsuzaki S; Nusbaum DJ; Maoz A; Oda K; Klar M; Roman LD; Sood AK
    Gynecol Oncol; 2021 Jan; 160(1):32-39. PubMed ID: 33196436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
    Kaban A; Topuz S; Saip P; Sozen H; Celebi K; Salihoglu Y
    J Obstet Gynaecol Can; 2017 Dec; 39(12):1163-1170. PubMed ID: 28784563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer.
    McAdams J; Ebott J; Jansen C; Kim C; Maiz D; Ou J; Hanley LC; Cruz P; James NE
    J Ovarian Res; 2024 Sep; 17(1):192. PubMed ID: 39342316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE.
    Mercier F; Bakrin N; Bartlett DL; Goere D; Quenet F; Dumont F; Heyd B; Abboud K; Marolho C; Villeneuve L; Glehen O; ;
    Ann Surg Oncol; 2018 Jun; 25(6):1668-1675. PubMed ID: 29637438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.